Alnylam Pharmaceuticals
Stock Forecast, Prediction & Price Target
Alnylam Pharmaceuticals Financial Estimates
Alnylam Pharmaceuticals Revenue Estimates
Alnylam Pharmaceuticals EBITDA Estimates
Alnylam Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $844.28M N/A | $1.03B 22.87% | $1.82B 76.23% | Avg: $2.30B Low: $1.99B High: $2.59B avg. 25.84% | Avg: $3.09B Low: $2.59B High: $3.51B avg. 34.45% | Avg: $4.00B Low: $3.36B High: $4.55B avg. 29.61% | Avg: $5.06B Low: $4.25B High: $5.75B avg. 26.20% |
Net Income
% change YoY
| $-852.82M N/A | $-1.13B -32.63% | $-440.24M 61.08% | Avg: $-226.35M Low: $-472.14M High: $288.53M avg. 48.58% | Avg: $307.52M Low: $-101.17M High: $1.14B avg. 235.86% | Avg: $700.81M Low: $555.19M High: $824.99M avg. 127.89% | Avg: $1.29B Low: $1.02B High: $1.52B avg. 84.33% |
EBITDA
% change YoY
| $-709.12M N/A | $-894.43M -26.13% | $-258.24M 71.12% | Avg: $-1.76B Low: $-1.98B High: $-1.52B avg. -581.88% | Avg: $-2.36B Low: $-2.69B High: $-1.98B avg. -34.45% | Avg: $-3.06B Low: $-3.48B High: $-2.57B avg. -29.61% | Avg: $-3.87B Low: $-4.40B High: $-3.25B avg. -26.20% |
EPS
% change YoY
| -$7.2 N/A | -$9.3 -29.16% | -$3.52 62.15% | Avg: -$1.64 Low: -$3.78 High: $2.31 avg. 53.33% | Avg: $2.35 Low: -$0.81 High: $9.2 avg. 243.15% | Avg: $5.61 Low: $4.44 High: $6.6 avg. 138.59% | Avg: $10.34 Low: $8.19 High: $12.18 avg. 84.33% |
Operating Expenses
% change YoY
| $1.41B N/A | $1.65B 17.04% | $1.80B 8.85% | Avg: $2.43B Low: $2.10B High: $2.74B avg. 35.14% | Avg: $3.27B Low: $2.74B High: $3.71B avg. 34.45% | Avg: $4.23B Low: $3.56B High: $4.81B avg. 29.61% | Avg: $5.35B Low: $4.49B High: $6.07B avg. 26.20% |
FAQ
What is Alnylam Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 124.16% in 2025-2028.
We have gathered data from 19 analysts. Their low estimate is -472.14M, average is -226.35M and high is 288.53M.
What is Alnylam Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 29.02% in 2025-2028.
We have gathered data from 23 analysts. Their low revenue estimate is $1.99B, average is $2.30B and high is $2.59B.
What is Alnylam Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 129.85% in 2025-2028.
We have gathered data from 19 analysts. Their low earnings per share estimate is -$3.78, average is -$1.64 and high is $2.31.
What is the best performing analyst?
In the last twelve months analysts have been covering Alnylam Pharmaceuticals stock. The most successful analyst is Whitney Ijem.